Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/1940-6207.CAPR-15-0077 http://scihub22266oqcxt.onion/10.1158/1940-6207.CAPR-15-0077 C4633385!4633385!26342024     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cancer+Prev+Res+(Phila) 2015 ; 8 (11): 1112-9 Nephropedia Template TP {{tp|p=26342024|t=2015. MAPRE1 as a plasma biomarker for early-stage colorectal cancer and adenomas |pdf=|usr=}}{{26342024}} gab.com Text MAPRE1 as a plasma biomarker for early-stage colorectal cancer and adenomas JO: Cancer Prev Res (Phila) http://www.kidney.de/pget.php?&tw=1&pmid=26342024 #FOAvip Blood-based biomarkers for early detection of colorectal cancer (CRC) could complement current approaches to CRC screening. We previously identified the APC-binding protein MAPRE1 as a potential CRC biomarker. Here we undertook a case-control validation study to determine the performance of MAPRE1 in detecting early CRC and colon adenoma and to assess the potential relevance of additional biomarker candidates. We analyzed plasma samples from 60 patients with adenomas, 30 with early CRC, 30 with advanced CRC, and 60 healthy controls. MAPRE1 and a set of 21 proteins with potential biomarker utility were assayed using high-density antibody arrays, and CEA was assayed using ELISA. The biologic significance of the candidate biomarkers was also assessed in CRC mouse models. Plasma MAPRE1 levels were significantly elevated in both patients with adenomas and patients with CRC compared with controls (P < 0.0001). MAPRE1 and CEA together yielded an area under the curve of 0.793 and a sensitivity of 0.400 at 95% specificity for differentiating early CRC from controls. Three other biomarkers (AK1, CLIC1, and SOD1) were significantly increased in both adenoma and early CRC patient plasma samples and in plasma from CRC mouse models at preclinical stages compared with controls. The combination of MAPRE1, CEA, and AK1 yielded sensitivities of 0.483 and 0.533 at 90% specificity and sensitivities of 0.350 and 0.467 at 95% specificity for differentiating adenoma and early CRC, respectively, from healthy controls. These findings suggest that MAPRE1 can contribute to the detection of early-stage CRC and adenomas together with other biomarkers. Twit Text FOAVip MAPRE1 as a plasma biomarker for early-stage colorectal cancer and adenomas ????Cancer Prev Res (Phila) http://www.kidney.de/pget.php?&tw=1&pmid=26342024 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26342024 #FOAvip English Wikipedia <ref>{{Cite pmid|26342024}}</ref> MAPRE1 as a plasma biomarker for early-stage colorectal cancer and adenomas #MMPMID26342024 Taguchi A; Rho Jh; Yan Q; Zhang Y; Zhao Y; Xu H; Tripathi SC; Wang H; Brenner DE; Kucherlapati M; Kucherlapati R; Boutin AT; Wang YA; DePinho RA; Feng Z; Lampe PD; Hanash SM Cancer Prev Res (Phila) 2015[Nov]; 8 (11): 1112-9 PMID26342024show ga Blood-based biomarkers for early detection of colorectal cancer (CRC) could complement current approaches to CRC screening. We previously identified the APC-binding protein MAPRE1 as a potential CRC biomarker. Here we undertook a case-control validation study to determine the performance of MAPRE1 in detecting early CRC and colon adenoma and to assess the potential relevance of additional biomarker candidates. We analyzed plasma samples from 60 patients with adenomas, 30 with early CRC, 30 with advanced CRC, and 60 healthy controls. MAPRE1 and a set of 21 proteins with potential biomarker utility were assayed using high-density antibody arrays, and CEA was assayed using ELISA. The biologic significance of the candidate biomarkers was also assessed in CRC mouse models. Plasma MAPRE1 levels were significantly elevated in both patients with adenomas and patients with CRC compared with controls (P < 0.0001). MAPRE1 and CEA together yielded an area under the curve of 0.793 and a sensitivity of 0.400 at 95% specificity for differentiating early CRC from controls. Three other biomarkers (AK1, CLIC1, and SOD1) were significantly increased in both adenoma and early CRC patient plasma samples and in plasma from CRC mouse models at preclinical stages compared with controls. The combination of MAPRE1, CEA, and AK1 yielded sensitivities of 0.483 and 0.533 at 90% specificity and sensitivities of 0.350 and 0.467 at 95% specificity for differentiating adenoma and early CRC, respectively, from healthy controls. These findings suggest that MAPRE1 can contribute to the detection of early-stage CRC and adenomas together with other biomarkers. äMAPRE1 as a plasma biomarker for early-stage colorectal cancer and ade(epmc).pdf DeepDyve Pubget Overpricing